Special Issue "Peptidylarginine Deiminases and Protein Deimination in Health and Disease"
Deadline for manuscript submissions: closed (31 December 2019).
Interests: Peptidylarginine deimnases; tissue remodelling; Extracellular Vesicles; CNS regeneration; Cancer; Mucosal Immunity; Innate Immunity; Stem Cells; comparative immunology; complement system; comparative animal models
Special Issues and Collections in MDPI journals
Interests: Parkinson's disease; protein deimination (citrullination); levodopa-induced dyskinesia; cervical dystonia
Peptidylarginine deiminases (PADs) are a group of calcium-dependent enzymes that are conserved throughout phylogeny and involved in physiological and pathophysiological processes. PADs cause post-translational deimination of proteins by converting arginine into citrulline (citrullination/deimination), resulting in structural and functional changes in target proteins.
The field of PADs has grown increasingly in the past few years with PADs and post-translational deimination being widely studied in autoimmune and neurodegenerative pathologies as well as in cancer. Protein deimination has, for example, been found to be involved in neo-epitope generation in autoimmunity, as well as neurodegeneration and inflammation, in epigenetic regulation via histone deimination in cancers and in the regulation of extracellular vesicle release.
The development of PAD inhibitors and PAD-knockout models has helped in elucidating some PAD-mediated roles in various pathologies. Protective roles for pharmacological PAD inhibitors have for example been shown in several animal models of autoimmunity and acute CNS injury, while regulatory roles for PAD inhibitors on histone modifications and extracellular vesicle release have been implicated in cancers, including sensitisation to chemotherapy.
While the physiological roles of PADs have been less studied, implications have been found in CNS development, embryo-preimplantation and in mucosal and innate immunity, among others. Post-translational protein changes, such as protein deimination, may facilitate protein moonlighting, an evolutionary acquired phenomenon where proteins are allowed to exhibit more than one physiologically relevant function within one polypeptide chain.
This Special Issue aims to collect state-of-the-art primary research studies and review articles from international experts and diverse leading groups in the field to update our current understanding of the contributions of PADs in both physiological and pathophysiological processes.
Dr. Sigrun Lange
Prof. Dr. Anthony P Nicholas
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Peptidylargine deiminases
- Posttranslational protein deimination
- CNS injury
- PAD antagonists
- PAD animal models